Answers are grounded in this paper and cite their sources.
Sarcopenia imposes a significant but modifiable economic burden on government-reimbursed healthcare services in the United States. Because the number of older Americans is increasing, the economic costs of sarcopenia will escalate unless effective public health campaigns aimed at reducing the occurrence of sarcopenia are implemented.
No takes yet. Share an insight, caveat, or question.
Janssen et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: